Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Sequenom Q1 Revenue Up on Increased Costs, Widened Losses

NEW YORK, April 30 - Sequenom today reported higher first-quarter revenues and increased net losses as strong demand for its genotyping systems and genetic services was outweighed by the increasing expense of the company's gene-discovery efforts.

 

Revenues for the quarter ended March 31 were $8.6 million compared with $5.2 million during the same period last year. Sequenom sold 11 MassARRAY systems during the quarter, it said.

 

Costs and expenses also climbed to $21 million in the first quarter 2002 from $14.2 million year over year.

 

Sequenom's net loss, including accounting changes, was $3.41 per diluted common share, totaling $127.9 million. Excluding those changes, loss for the quarter was $11 million, or $.29 per diluted share, compared with $7 million, or $.29 per diluted share, during the first quarter 2001.

 

The company held cash, cash equivalents, and short-term investments of $126.1 million as of March 31.

 

For more information, click here.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.